Related Experiment Video
Updated: Jun 9, 2025
10:01
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
6.3K
Beyond Primary HER2 Expression: Trastuzumab Deruxtecan's Efficacy in Brain Metastasis
Glori Das1,2, Stephen T C Wong1,2, Hong Zhao1
1Department of Systems Medicine and Bioengineering, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX 77030, USA.
Cancers
|October 26, 2024
Summary
Trastuzumab deruxtecan shows promise for brain metastases in HER2-positive breast cancer. This therapy may also benefit patients with HER2-low or HER2-null tumors, offering new hope for difficult-to-treat cases.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- The DESTINY-Breast12 study evaluated Trastuzumab deruxtecan (T-DXd) efficacy in advanced HER2-positive breast cancer.
- Brain metastases present a significant challenge in breast cancer treatment.
- Current treatment options for brain metastases are limited, especially for HER2-low or HER2-null subtypes.
Discussion:
- The commentary highlights the potential of T-DXd beyond its established indications.
- Expanding T-DXd use to HER2-low and HER2-null brain metastases could address an unmet clinical need.
- This suggests a broader therapeutic role for T-DXd in metastatic cancer.
Key Insights:
- T-DXd demonstrates efficacy in HER2-positive advanced breast cancer with brain metastases.
- Evidence suggests T-DXd may be effective for brain metastases originating from HER2-low or HER2-null primary tumors.
- This broadens the potential application of T-DXd in neuro-oncology.
Outlook:
- Further clinical investigation is warranted to confirm T-DXd efficacy in HER2-low/HER2-null brain metastases.
- T-DXd could represent a novel treatment strategy for patients with challenging brain metastases.
- This research may lead to improved outcomes for a wider range of breast cancer patients with metastatic disease.
